Recent studies have indicated that the mammalian target of rapamycin inhibitor rapamycin promotes erythroid differentiation in pluripotent stem cells and significantly improves the anemic phenotype in patients with Mitochondrial Leukoencephalopathy, Lactic Acidosis, and Stroke-like episodes (24). This evidence concerns the gene MTOR and lactic acidosis.